Nano-X Imaging Ltd., a development-stage company, develops, produces, and commercializes digital X-ray source technology for the medical imaging industry worldwide. More Details
Excellent balance sheet with moderate growth potential.
Share Price & News
How has Nano-X Imaging's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: NNOX is more volatile than 75% of US stocks over the past 3 months, typically moving +/- 15% a week.
Volatility Over Time: NNOX's weekly volatility has decreased from 22% to 15% over the past year, but is still higher than 75% of US stocks.
7 Day Return
US Medical Equipment
1 Year Return
US Medical Equipment
Return vs Industry: Insufficient data to determine how NNOX performed against the US Medical Equipment industry.
Return vs Market: Insufficient data to determine how NNOX performed against the US Market.
Long-Term Price Volatility Vs. Market
How volatile is Nano-X Imaging's share price compared to the market and industry in the last 5 years?
Simply Wall St News
1 week ago | Simply Wall StWe're Not Worried About Nano-X Imaging's (NASDAQ:NNOX) Cash Burn
2 months ago | Simply Wall StHere's What Nano-X Imaging Ltd.'s (NASDAQ:NNOX) Shareholder Ownership Structure Looks Like
4 months ago | Simply Wall StNano-X Imaging (NASDAQ:NNOX) Is In A Strong Position To Grow Its Business
Is Nano-X Imaging undervalued compared to its fair value and its price relative to the market?
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: NNOX ($21.91) is trading below our estimate of fair value ($319.3)
Significantly Below Fair Value: NNOX is trading below fair value by more than 20%.
Price To Earnings Ratio
PE vs Industry: NNOX is unprofitable, so we can't compare its PE Ratio to the US Medical Equipment industry average.
PE vs Market: NNOX is unprofitable, so we can't compare its PE Ratio to the US market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate NNOX's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: NNOX is overvalued based on its PB Ratio (4.6x) compared to the US Medical Equipment industry average (4.4x).
How is Nano-X Imaging forecast to perform in the next 1 to 3 years based on estimates from 4 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: NNOX is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (2%).
Earnings vs Market: NNOX is forecast to become profitable over the next 3 years, which is considered above average market growth.
High Growth Earnings: NNOX's is expected to become profitable in the next 3 years.
Revenue vs Market: Insufficient data to determine if NNOX's revenue is forecast to grow faster than the US market.
High Growth Revenue: Insufficient data to determine if NNOX's revenue is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if NNOX's Return on Equity is forecast to be high in 3 years time
How has Nano-X Imaging performed over the past 5 years?
Last years earnings growth
Earnings and Revenue History
Quality Earnings: NNOX is currently unprofitable.
Growing Profit Margin: NNOX is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: Insufficient data to determine if NNOX's year-on-year earnings growth rate was positive over the past 5 years.
Accelerating Growth: Unable to compare NNOX's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: NNOX is unprofitable, making it difficult to compare its past year earnings growth to the Medical Equipment industry (11.1%).
Return on Equity
High ROE: NNOX has a negative Return on Equity (-21.8%), as it is currently unprofitable.
How is Nano-X Imaging's financial position?
Financial Position Analysis
Short Term Liabilities: NNOX's short term assets ($222.2M) exceed its short term liabilities ($18.3M).
Long Term Liabilities: NNOX's short term assets ($222.2M) exceed its long term liabilities ($992.0K).
Debt to Equity History and Analysis
Debt Level: NNOX is debt free.
Reducing Debt: NNOX had no debt 5 years ago.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: NNOX has sufficient cash runway for more than 3 years based on its current free cash flow.
Forecast Cash Runway: Insufficient data to determine if NNOX has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.
What is Nano-X Imaging current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate NNOX's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate NNOX's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if NNOX's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if NNOX's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of NNOX's dividend in 3 years as they are not forecast to pay a notable one for the US market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Ran Poliakine (52 yo)
Mr. Ran Poliakine has been Chairman of Nano-X Imaging Ltd. since August 21, 2020 and has been its Chief Executive Officer since September 2019. He is the Founder of Wellsense USA, Inc. and Wellsense Ltd. H...
Experienced Management: NNOX's management team is not considered experienced ( 1.1 years average tenure), which suggests a new team.
Experienced Board: NNOX's board of directors are not considered experienced ( 1 years average tenure), which suggests a new board.
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Dilution of Shares: NNOX only recently listed within the past 12 months.
Nano-X Imaging Ltd.'s company bio, employee growth, exchange listings and data sources
- Name: Nano-X Imaging Ltd.
- Ticker: NNOX
- Exchange: NasdaqGM
- Founded: 2011
- Industry: Health Care Equipment
- Sector: Healthcare
- Market Cap: US$1.043b
- Shares outstanding: 47.60m
- Website: https://www.nanox.vision
Number of Employees
- Nano-X Imaging Ltd.
- Communications Center
- Neve Ilan
Nano-X Imaging Ltd., a development-stage company, develops, produces, and commercializes digital X-ray source technology for the medical imaging industry worldwide. Its X-ray source is based on a novel dig...
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2021/05/15 22:27|
|End of Day Share Price||2021/05/14 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.